← Katalog Appraisal
TAPublishedBlood and immune system conditions / Blood and bone marrow cancers· 2026-02-17
TA1132
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)
0 item